UCI Health has launched the first U.S. clinical trial to evaluate riluzole, an ALS medication, for treating cancer-related cognitive impairment, commonly known as “chemo brain.” Led by Alexandre Chan, PharmD, MPH, founding chair and professor of the UC Irvine Department of Clinical Pharmacy Practice, the phase 2a trial investigates whether riluzole can elevate brain-derived neurotrophic factor (BDNF) levels and improve cognitive function in cancer survivors. The randomized, double-blind, placebo-controlled study will enroll 39 patients and builds on a $2.4 million NIH grant awarded to Chan and neuroscientist Munjal Acharya, PhD. This pioneering research aims to restore cognitive health in cancer patients, emphasizing quality of life alongside cancer survival.